GlassScriptPhysician profile
Benjamin R Burkett
NPI 1538322052
$4,581.10
in general payments reported to CMS, 2019-2025
28 companies · $1,395 in 2025
The $1,395 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $31.68 · 2021: $71.46 · 2022: $504 · 2023: $1,214 · 2024: $1,239 · 2025: $1,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,847.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $579.31 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $520.96 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $515.34 | 2019-2025 | |
| Glaxosmithkline, LLC. | $503.38 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $309.74 | 2022-2025 | Synthroid, Ubrelvy |
| Lilly USA, LLC | $305.34 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $286.96 | 2022-2025 | Xifaxan, Trulance, Cycloset |
| Abbott Laboratories | $241.48 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| E.R. Squibb & Sons, L.L.C. | $181.94 | 2022-2025 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $136.36 | 2024-2025 | |
| Exact Sciences Corporation | $132.23 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $127.52 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $113.31 | 2022-2024 | |
| Astellas Pharma US INC | $101.23 | 2023-2024 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $87.61 | 2023-2025 | Gemtesa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $84.79 | 2023-2025 | Otezla, Repatha, Krystexxa |
| Sanofi-Aventis U.S. LLC | $73.63 | 2022-2023 | |
| Esperion Therapeutics, INC. | $56.90 | 2023-2025 | Nexletol |
| Inspire Medical Systems, INC. | $49.72 | 2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $31.35 | 2023-2024 | Quviviq |
| Phathom Pharmaceuticals, INC. | $25.63 | 2024-2025 | Voquezna |
| Evoke Pharma, INC. | $21.18 | 2024 | |
| Xeris Pharmaceuticals, INC. | $18.12 | 2025 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $17.98 | 2025 | |
| Ibsa Pharma INC. | $17.10 | 2024 | Tirosint, Licart |
| Paratek Pharmaceuticals, INC. | $14.98 | 2024 | Nuzyra |
| Shield Therapeutics INC | $14.90 | 2023 | Accrufer |
| Kowa Pharmaceuticals America, INC. | $12.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Burkett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.